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16mg/kg/day. The target area under the curve (AUC) was deﬁned
as 17.500 g*h/l and was assessed on day 1 and day 4 based on 3
blood samples. Dose adjustment was performed before the second
dose. Primary endpoint was A&E, secondary endpoints were veno-
occlusive disease (VOD), graft versus host disease (GvHD). A risk
factor analyses was performed using logistic regression.
Results: Between 6/2003 and 6/2006 60 pts were included (30
IVdtBU and 30 POBU). The IVdtBU and POBU groups were
comparable regarding age, sexe, indication for SCT, match-grade
and donor-source. The A&E rates for the IVdtBU and POBU
were 83.3% and 40%, respectively (OR 7.3; 95% CI 2,1-26;
p0.002). VOD occurred in 33% and 13% of patients, respectively
(P0,1). No difference in GvHD (grade2) was found. Average
AUC after the ﬁrst dose was 20.710 g*h/l and decreased after
targeting to 18.920 g*h/l. However, interpatient variation re-
mained comparable. The pharmacokinetic data showed a large
difference between the clearances of busulfan in children as com-
pared to adults. Clearance correlated well to body surface area and
seemed to be constant at all ages, whereas clearance divided to
bodyweight decreased as a function of age.
Conclusions: IVdtBU resulted in higher A&E rates compared to
POBU. A non-signiﬁcantly trend to more VOD in the IVdtBU
group was observed. Because of the generally high AUC of day 1
starting dose might be lowered. Once daily dosing of IV busulfan
with TDM was feasible in routine clinical practice and improved
the A&E rates for SCT in children.
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Background: Hurler’s syndrome (HS), the most severe form of
mucopolysaccharidosis type-I causes progressive deterioration of
the central nervous system and death in childhood. Allogeneic-
stem cell transplantation (SCT) before the age of two years halts
disease progression and prolongs life. Graft-failure and mixed
chimerism limits the success of SCT for HS. (Unrelated) cord
blood grafts are suggested to be a good alternative source for bone
marrow.
Methods: Patient registered to EUROCORD-database and
EBMT-Hurler syndrome database were included. Between 1991
and 2004 forty-two patients received an (unrelated)-cord blood
transplant. The children were evaluated for engraftment, adverse
event and effects on disease symptoms. A risk factor analyses was
performed using logistic regression.
Results: From 40 patients enough data was available. After a
median follow up period of 14 (7-84) mths the “alive and en-
grafted” rate was 69% after ﬁrst SCT. Donors used were: 4 HLA-
identical family and 36 unrelated cord blood (23 mismatched: 18
5/6-matched and ﬁve 4/6-matched). With the exception of 2, all
patients received a myeloablative conditioning regimen. Cell dose
used was median 7.9 (1.5-32) *107 NC/kg and 2,6 (0,7-25) *105
CD34/Kg. In multivariate logistic regression analyses, year of
transplantation (2000 vs. 2001: A&E 40 vs 84%: OR 7,5 range
1,7-30, p0.007) and NC-dose of less than 5*107 NC/kg (OR 6,4,
range 1,7-39: p 0.045) were found to be risk factors for graft-
failure. Only 2 of the 27 patients A&E patients showed a mixed
chimerism (86 and 92%: still increasing). All patients had normal
enzyme levels. Acute-GvHD (grade1) was observed in 15%,
while chronic-GvHD was seen in 19% (extensive 8%) of patients
at risk. SCT improved somatic features of HS.
Conclusion: Outcome following cord blood SCT for Hurler’s
syndrome is encouraging. (U)CB is a good alternative stem cell
source and might even be preferential since cord-blood appeared
to increase the likelihood of sustained engraftment resulting in
full-donor chimerism and normal enzyme levels.
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Background: Although human herpes virus 6 (HHV6) is known
to reactivate during haematopoietic cell transplantation (HCT)
and is suggested to be associated with severe clinical manifestations
in adults, the clinical signiﬁcance in children remains controversial.
In this study we investigated the incidence of HHV6 reactivation
and HCT-associated morbidity and mortality in children.
Methods: Between 1/2004 and 4/2006 59 patients, median age
6.6y (0.1-18.1), underwent 68 allogeneic HCTs. By quantitative
PCR HHV6, EBV, CMV and adenovirus (AdV)-plasma loads were
measured once a week. Clinical features, engraftment, number of
transfusions, HCT-associated mortality and morbidity (like
GvHD) were monitored. Antiviral treatment for HHV-6 reactiva-
tion was only given from 4/2005 for those with clinical symptoms
assumed to be associated with HHV6. HHV6 reactivations were
grouped in group I (no HHV6), group II (loads 1000cp/mL) and
group III (loads1000cp/mL). CMV, EBV and AdV-reactivations
were treated according to local guidelines. A risk factor analyses
was performed using logistic regression.
Results: 36 HLA-id and 23 HLA non-id grafts were used: 44
bone marrow/PBSCs and 15 cord blood grafts. Median follow up
was 17 (5-35)mths. HHV6 reactivation occurred in 40/59 (67%)
with 33/40 (82%) occurring within the ﬁrst 30 d post-HCT. 23/59
(39%) had HHV6 loads above 1000cp/mL (group III). Groups did
not differ regarding sex, age, donor source or HLA-disparity. In
multivariate analysis HHV6 reactivation was associated with a
lower survival in group III (OR 0,16; range 0,03-0,89; p0.035) as
well as with more multiple viral reactivations (p0,049: OR 5,5;
range 1,1-29) were seen in this group. In 11/13 multiple viral
reactivation HHV6 was the ﬁrst viral reactivation. There was a
non-signiﬁcant trend for more grade 2-4 acute-GvHD (p0,058
OR 4,3; range 0,8-18) in group III. HHV6 didnot inﬂuence period
of neutro-trombocytopenia.
Conclusion: HHV6 reactivation is common after HCT in chil-
dren and is associated with a higher rate of multiple viral reacti-
vations, aGvHD and with a lower survival rate. Although the exact
role of HHV6 reactivation in transplantation associated morbidity
and mortality has to be elucidated, early detection and initiation of
therapy might inﬂuence the outcome.
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Introduction:
Advanced Practice Stem Cell Transplant (SCT) Nursing pro-
vides unique challenges associated with the medical science of
SCT, current healthcare environment and intense relationships
with patients and families due to the demanding nature of this
therapy. Although job satisfaction among nurses has been discussed
in the literature, the focus has been on work related and psycho-
logical stresses of SCT staff nurses working in inpatient SCT units
1,2. To date little if any research has been done exploring job
satisfaction speciﬁc to Advanced Practice SCT Nurses (APSCTN)
who have become integral members of the pediatric SCT team.
Methods:
Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Nursing Discipline members completed a simple questionnaire
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